Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Posted: December 2018 In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical...

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to...

By Ross Soo, MB BS, PhD, FRACP Posted: December 2018 The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs)...

Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC

By Mariano Provencio-Pulla, MD, PhD Posted: December 2018 Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of...

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

By Kara Nyberg, PhD Posted: August 2018 The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint...

Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care

By Kara Nyberg, PhD Posted: August 2018 Treatment advances for metastatic squamous cell carcinoma have long lagged behind those for other NSCLC subtypes, forcing patients with...

AACR 2018: First-Line Management of Advanced NSCLC Enters New Era

By Corey Langer, MD, IASLC Lung Cancer News Editor Posted: June 2018 The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189,...

PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

By Fred R. Hirsch, MD, PhD Posted: April 2018 Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of...

PACIFIC Trial Leads to Durvalumab Approval in United States

The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are...

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For...

Immunotherapy Adverse-Event Treatment Resource Guide

The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline...

Meeting News